PDF(Pubmed)
Abstract：
UNASSIGNED: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durvalumab became clinically available.
UNASSIGNED: We reviewed the clinical records of patients with stage III non-small cell lung cancer (NSCLC) treated with CCRT and IMRT at seven centers in Japan and investigated relapse and survival from May 2018 to December 2019. The primary endpoint of this report was progression-free survival (PFS).
UNASSIGNED: Among 107 patients enrolled in the study, 87 were sequentially administered durvalumab. From CCRT commencement, patients were followed up for a median period of 29.7 months. The median PFS at the end of the CCRT was 20.7 months. Among the 87 patients, 58 experienced disease relapses, of whom 36 (62.1 %) had distant metastases. Multivariate Cox regression analysis revealed that a favorable response to CCRT, a radiation dose ≥ 62 Gy, and stage IIIA NSCLC were associated with prolonged PFS (all P = 0.04). Multivariate logistic regression by landmark analysis revealed that mortality risk factors were durvalumab treatment duration ≤ 11.7 months, a lower maximum grade of immune-related adverse events, FEV1 < 2805 mL, and radiation dose < 62 Gy (P = 0.01, 0.01, 0.03, and 0.04, respectively).
UNASSIGNED: In patients with NSCLC receiving CCRT using IMRT, long PFS was associated with a better response to CCRT, stage IIIA NSCLC, and an increased radiation dose. The duration of durvalumab consolidation also played an essential role in the survival of patients receiving CCRT with IMRT. (250 words).
UNASSIGNED: We reviewed the clinical records of patients with stage III non-small cell lung cancer (NSCLC) treated with CCRT and IMRT at seven centers in Japan and investigated relapse and survival from May 2018 to December 2019. The primary endpoint of this report was progression-free survival (PFS).
UNASSIGNED: Among 107 patients enrolled in the study, 87 were sequentially administered durvalumab. From CCRT commencement, patients were followed up for a median period of 29.7 months. The median PFS at the end of the CCRT was 20.7 months. Among the 87 patients, 58 experienced disease relapses, of whom 36 (62.1 %) had distant metastases. Multivariate Cox regression analysis revealed that a favorable response to CCRT, a radiation dose ≥ 62 Gy, and stage IIIA NSCLC were associated with prolonged PFS (all P = 0.04). Multivariate logistic regression by landmark analysis revealed that mortality risk factors were durvalumab treatment duration ≤ 11.7 months, a lower maximum grade of immune-related adverse events, FEV1 < 2805 mL, and radiation dose < 62 Gy (P = 0.01, 0.01, 0.03, and 0.04, respectively).
UNASSIGNED: In patients with NSCLC receiving CCRT using IMRT, long PFS was associated with a better response to CCRT, stage IIIA NSCLC, and an increased radiation dose. The duration of durvalumab consolidation also played an essential role in the survival of patients receiving CCRT with IMRT. (250 words).
摘要：
UNASSIGNED：目前，调强放疗（IMRT）比三维适形放疗更常用于明确的胸部放疗。我们检查了durvalumab临床可用后同步放化疗（CCRT）和IMRT的疗效。
UNASSIGNED：我们回顾了日本七个中心接受CCRT和IMRT治疗的III期非小细胞肺癌（NSCLC）患者的临床记录，并调查了2018年5月至2019年12月的复发和生存率。该报告的主要终点是无进展生存期（PFS）。
未经证实：在参与研究的107名患者中，87例患者依次服用durvalumab。从CCRT开始，患者的中位随访时间为29.7个月.CCRT结束时的中位PFS为20.7个月。在87名患者中，58次经历疾病复发，其中36例（62.1%）有远处转移。多因素Cox回归分析显示，对CCRT的反应良好，辐射剂量≥62Gy，和IIIA期NSCLC与延长的PFS相关（所有P=0.04）。多因素logistic回归分析显示死亡危险因素为durvalumab治疗时间≤11.7个月,免疫相关不良事件的最高等级较低，FEV1<2805mL，和辐射剂量<62Gy（分别为P=0.01、0.01、0.03和0.04）。
未经批准：在接受使用IMRT的CCRT的NSCLC患者中，长PFS与更好的CCRT反应相关，IIIA期NSCLC,和增加的辐射剂量。durvalumab巩固的持续时间在接受CCRT和IMRT的患者的生存中也起着重要作用。（250字）
UNASSIGNED：我们回顾了日本七个中心接受CCRT和IMRT治疗的III期非小细胞肺癌（NSCLC）患者的临床记录，并调查了2018年5月至2019年12月的复发和生存率。该报告的主要终点是无进展生存期（PFS）。
未经证实：在参与研究的107名患者中，87例患者依次服用durvalumab。从CCRT开始，患者的中位随访时间为29.7个月.CCRT结束时的中位PFS为20.7个月。在87名患者中，58次经历疾病复发，其中36例（62.1%）有远处转移。多因素Cox回归分析显示，对CCRT的反应良好，辐射剂量≥62Gy，和IIIA期NSCLC与延长的PFS相关（所有P=0.04）。多因素logistic回归分析显示死亡危险因素为durvalumab治疗时间≤11.7个月,免疫相关不良事件的最高等级较低，FEV1<2805mL，和辐射剂量<62Gy（分别为P=0.01、0.01、0.03和0.04）。
未经批准：在接受使用IMRT的CCRT的NSCLC患者中，长PFS与更好的CCRT反应相关，IIIA期NSCLC,和增加的辐射剂量。durvalumab巩固的持续时间在接受CCRT和IMRT的患者的生存中也起着重要作用。（250字）
